Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Abstract Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm mi...

Full description

Bibliographic Details
Main Authors: Emek Kocatürk, Emel Bülbül Başkan, Özlem Su Küçük, Mustafa Özdemir, Sinem Örnek, Pelin Kuteyla Can, Eda Hașal, Burhan Engin, Nilgün Atakan, Erkan Alpsoy
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia 2022-09-01
Series:Anais Brasileiros de Dermatologia
Subjects:
Biomarker
Chronic urticaria
Cyclosporine
Omalizumab
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962022000500592&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962022000500592&tlng=en

Similar Items